PPT-Switch to DRV/r + 3TC DUAL Study

DRVr 800100 3TC 300 QD N 126 N 123 DRVr ABC3TC or TDFFTC QD Design Randomisation 1 1 Openlabel Objective Non inferiority of DRVr 3TC at W48 HIV RNA lt 50 cmL by intention to treatexposed snapshot analysis lower margin of the 2sided 95 CI for the difference 12 80 power. of HIV Infection. Dual therapies without NRTIs. Jean-Guy Baril, MD. Clinique médicale du Quartier Latin. CHUM. This activity is supported by. an educational grant from:. Received consultant, investigator or speaker honoraria/grants from the following companies . Effects of Atazanavir, . Raltegravir. . or Darunavir with FTC/Tenofovir . on Biomarkers . of Systemic Inflammation, Macrophage and T-Cell Activation: . ACTG A5260s . T. . Kelesidis. , . T.T.T. . Tran, . STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . PROBE . Study. PROBE Study: switch to DRV/r + RPV . Design. Age ≥ 18 years. HIV+. No previous resistance to study drugs. HIV-1 RNA. < 50 c/ml ≥ 6 months. On stable (≥ 6 months) . PI/r + 2 NRTI (TDF/FTC or ABC/3TC). ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . Geneva, March 19 - 20 , 2015 1 | Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato, Nathan Ford Update on CADO/PADO: what are the challenges in using the current guidelines an Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N =. 127. N =. 123. LPV/. r. bid + 3TC/FTC . qd. Design. Randomisation*. 1: 1. Open-label. Objective. Primary Endpoint :. proportion without treatment failure at W48 . Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. Virologically. Suppressed. OLE Trial. LPV-RTV + . 3TC vs. LPV. -RTV + 2 NRTIs. in . Virologically. Suppressed. OLE: . Study Design. Source: . Arribas. JR, et al. . Lancet Infect Dis. . 2015;15:. 785-92.. Dr. Kay Mahomed. Netcare. Garden City Clinic. Mayfair West. 083 294 7007. 011 495 5243. overall_1_132245246515670924 columns_1_132245246515670924 . Goals of . Treatment. ART is the cornerstone of HIV . Identifier: . NCT02770508 . Dual therapy based on . DRV/r . plus 3TC in HIV-1 naïve patients: . Global 48 . week results from ANDES . Study. . Maria Ines Figueroa on behalf of the ANDES study group. ROCKET II. Switching to TDF-FTC from ABC-3TC . for Hyperlipidemia . ROCKET II. : Study Design. Source: Behrens G, et al. . Antivir. . Ther. . . 2012;17:1011-20.. TDF-FTC + LPV-RTV. (. n = . 42). ABC-3TC + LPV-RTV. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. DRIVE SHIFT. Switch to Doravirine-TDF-3TC versus Continued Baseline Regimen. DRIVE SHIFT: Design. Source: Johnson M, et al. J . Acquir. . Immun. . Defic. . Syndr. . 2019;81:463-72.. Design: . Open-label, non-inferiority trial in adults with suppressed HIV RNA while taking 2 NRTIs plus anchor drug, randomized (2:1) to immediately switch to fixed-dose .